Login
$KLRS
$1.46 -$0.11 (7.3%) Live

$KLRS SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

Preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027

26 Oct 2026 SCHEDULE 13G
28 Aug 2026 Form 4: Vandekop Amy O'Leary, VP, Corporate Controller

Granted 10,000 Stock Option (Right to Buy)

11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027

03 Aug 2026 Form 4: Keating Laurie, Director

Granted 18,000 Stock Option (Right to Buy)

03 Aug 2026 Form 3: Keating Laurie, Director

No securities owned

27 Jul 2026 Form 3: Vandekop Amy O'Leary, See Remarks

Holds 948 shares of Common Stock

20 Jul 2026 Form 4: Bayko Liisa Ann, Chief Financial Officer

Granted 220,000 Stock Option (Right to Buy)

20 Jul 2026 Form 3: Bayko Liisa Ann, Chief Financial Officer

No securities owned

20 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of July 7, 2026 by and between Kalaris Therapeutics, Inc. (the “Company”), and Liisa Bayko (the “Executive”) (together, the “Parties”).

17 Jul 2026 8-K: Regulation FD Disclosure; Other Events

Forward-Looking Statements & Disclaimer This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as am...

06 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

04 Jun 2026 Form 4: Jovan-Embiricos Morana, Director

Granted 9,000 Stock Option (Right to Buy)

04 Jun 2026 Form 4: Ferrara Napoleone, Director

Granted 9,000 Stock Option (Right to Buy)

04 Jun 2026 Form 4: Hallal David, Director

Granted 9,000 Stock Option (Right to Buy)

04 Jun 2026 Form 4: Akkaraju Srinivas, Director

Granted 9,000 Stock Option (Right to Buy)

04 Jun 2026 Form 4: Dybbs Michael, Director

Granted 9,000 Stock Option (Right to Buy)

04 Jun 2026 Form 4: Adamis Anthony P, Director

Granted 9,000 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support